My daughter, Mallory, died in 2017 at the age of 25 from a multiply resistant bacterial lung infection that followed a double-lung transplant necessitated by cystic fibrosis. In the weeks before her death, my wife, Diane Shader Smith, and I sought out and obtained an innovative yet underused treatment for antibiotic-resistant bacteria known as phage therapy. Her physicians administered the therapy, but it was too late to save Mallory’s life. An autopsy, though, confirmed that the phages had reached their target and had started to work.
Resistance of bacteria, fungi, and other microbes to drugs designed to keep them in check, collectively known as antimicrobial resistance, poses one of the gravest threats to global health today. With bacteria having developed resistance to most antibiotics, and a dwindling number of new antibiotics being developed, the world faces a future in which common infections are all but untreatable, and where routine surgeries become life-threatening. Against this bleak vision of the future, phage therapy offers a beacon of hope. For it to shine, though, the Food and Drug Administration must loosen its restrictions to facilitate the broader use of phage therapy in the United States.
Click this link for the original source of this article.
Author: Mark H. Smith
This content is courtesy of, and owned and copyrighted by, https://www.statnews.com and its author. This content is made available by use of the public RSS feed offered by the host site and is used for educational purposes only. If you are the author or represent the host site and would like this content removed now and in the future, please contact USSANews.com using the email address in the Contact page found in the website menu.